1 Global Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage Retrospective Market Scenario in Sales Volume by Region: 2019-2024
From 2019 to 2024, the sales volume of pharmaceutical continuous manufacturing (PCM) equipment for solid dosage has shown a steady increase across all regions. North America has experienced the most significant growth, with sales volumes rising from 8 sets in 2019 to an expected 18 sets in 2024. Europe has maintained a relatively stable growth, starting with 10 sets in 2019 and projected to reach 16 sets by 2024. The Asia Pacific region has also seen a gradual increase, from 6 sets in 2019 to a forecasted 13 sets in 2024. Latin America and the Middle East & Africa (MEA) have shown the least growth, with sales volumes remaining at 1 set throughout the period.
The data indicates a positive trend in the global sales of PCM equipment for solid dosage, with a total increase from 25 sets in 2019 to a forecasted 48 sets in 2024. The growth is primarily driven by North America and Europe, which together account for the majority of the increase. Asia Pacific contributes moderately to this growth, while Latin America and MEA show minimal change, suggesting a slower adoption rate or market saturation in these regions. Overall, the global market for PCM equipment in solid dosage is expected to continue expanding.
Table Global Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage Sales Volume (Sets) by Regions (2019-2024)
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
North America | 8 | 11 | 12 | 14 | 16 | 18 |
Europe | 10 | 10 | 11 | 15 | 15 | 16 |
Asia Pacific | 6 | 6 | 8 | 9 | 11 | 13 |
Latin America & MEA | 1 | 0 | 1 | 1 | 1 | 1 |
Total | 25 | 27 | 32 | 39 | 43 | 48 |
2 Global Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage Retrospective Market Scenario in Revenue by Region: 2019-2024
The global revenue from pharmaceutical continuous manufacturing (PCM) equipment for solid dosage has shown a consistent upward trend from 2019 to 2024. North America has been the highest contributor, with revenues increasing from $65.99 million in 2019 to a projected $152.15 million in 2024. Europe follows with a slight dip in 2020 but then shows an increase, reaching a forecasted $132.85 million in 2024. The Asia Pacific region started with lower revenue but has been steadily increasing, projected to reach $99.59 million by 2024. Latin America and the Middle East & Africa (MEA) have the smallest share, with revenues remaining relatively flat at around $7 million throughout the period. The total global revenue has grown from $199.25 million in 2019 to an expected $392.02 million in 2024, indicating a strong market expansion in the PCM equipment sector for solid dosage.
North America and Europe are the key drivers of this growth, with North America showing the most significant increase. Asia Pacific also contributes to the growth, albeit at a slower pace. Latin America and MEA have a minimal impact on the overall revenue growth, suggesting a slower market penetration or lower adoption rate in these regions. The overall upward trend in revenue aligns with the increasing adoption of PCM technology, which is expected to continue as the industry moves towards more efficient and continuous manufacturing processes.
Table Global Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage Revenue (M USD) by Region (2019-2024)
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
North America | 65.99 | 89.36 | 101.62 | 119.37 | 134.49 | 152.15 |
Europe | 81.02 | 79.80 | 91.50 | 125.63 | 123.85 | 132.85 |
Asia Pacific | 44.97 | 42.77 | 61.26 | 68.79 | 83.49 | 99.59 |
Latin America & MEA | 7.26 | 0.00 | 7.45 | 7.50 | 7.40 | 7.44 |
Total | 199.25 | 211.94 | 261.84 | 321.30 | 349.23 | 392.02 |
3 Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage Market Sales Volume (Sets) Forecast by Regions (2024-2030)
During the forecast period from 2024 to 2030, the sales volume of Pharmaceutical Continuous Manufacturing (PCM) equipment for solid dosage is expected to show a promising growth trajectory across all regions. North America is anticipated to lead with an increase from 18 sets in 2024 to 36 sets in 2030, reflecting a steady annual growth. Europe is also expected to show a consistent rise, starting from 16 sets and reaching 30 sets by 2030. The Asia Pacific region follows a similar upward trend, with sales volume increasing from 13 sets to 26 sets over the same period. Latin America and the Middle East & Africa (MEA) show the slowest growth, with only a slight increase from 1 set to 2 sets by 2030. The total global sales volume is projected to increase significantly, from 48 sets in 2024 to 94 sets in 2030.
Table Global Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage Sales Volume (Sets) Forecast by Regions (2024-2030)
| 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
North America | 18 | 21 | 23 | 26 | 28 | 32 | 36 |
Europe | 16 | 18 | 20 | 23 | 25 | 27 | 30 |
Asia Pacific | 13 | 15 | 17 | 19 | 21 | 24 | 26 |
Latin America & MEA | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
Total | 48 | 55 | 61 | 69 | 76 | 85 | 94 |
4. Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage Market Sales Revenue (M USD) Forecast by Regions (2024-2030)
The projected sales revenue for pharmaceutical continuous manufacturing (PCM) equipment for solid dosage is anticipated to witness significant growth globally from 2024 to 2030. North America is expected to experience a substantial increase, with revenues rising from $152.15 million in 2024 to $308.87 million by 2030. Europe follows with a projected increase from $132.85 million to $254.11 million over the same period. The Asia Pacific region also shows a positive trend, with revenues expected to grow from $99.59 million to $203.52 million. Latin America and the Middle East & Africa (MEA) exhibit a more modest increase, with revenues projected to rise from $7.44 million to $15.18 million by 2030. Overall, it is projected that by 2030, the total global sales revenue will soar from $392.02 million in 2024 to $781.67 million, indicating that there is still significant potential in the market for PCM equipment for solid dosage in the future.
Table Global Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage Sales Revenue (M USD) Forecast by Regions (2024-2030)
| 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
North America | 152.15 | 175.97 | 196.91 | 226.17 | 242.36 | 272.54 | 308.87 |
Europe | 132.85 | 150.10 | 167.11 | 193.18 | 210.23 | 227.81 | 254.11 |
Asia Pacific | 99.59 | 115.37 | 131.07 | 146.91 | 163.55 | 187.73 | 203.52 |
Latin America & MEA | 7.44 | 7.47 | 7.49 | 7.52 | 15.07 | 15.12 | 15.18 |
Total | 392.02 | 448.91 | 502.58 | 573.78 | 631.21 | 703.19 | 781.67 |
5. North America Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage Market Analysis by Major Countries
From 2019 to 2024, the United States has dominated the North American market for pharmaceutical continuous manufacturing (PCM) equipment for solid dosage, with a market share consistently above 90%, peaking at 100% in 2020 and 2022. Canada’s market share, on the other hand, has been significantly lower and more variable, reaching a high of 12.63% in 2019 and dropping to 0% in 2020 and 2022, with a projected increase to 11.22% by 2024. Despite these fluctuations, the total market share for both countries remains at 100%, underscoring the significant role of the United States in driving the overall market in North America.
Table North America Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage Revenue Market Share by Countries (2019-2024)
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024F |
United States | 87.38% | 100.00% | 91.58% | 100.00% | 93.69% | 88.78% |
Canada | 12.63% | 0.00% | 8.42% | 0.00% | 6.31% | 11.22% |
Total | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
5.1 United States Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage Market Revenue and Growth Analysis (2019-2024)
The market revenue for pharmaceutical continuous manufacturing (PCM) equipment for solid dosage in the United States exhibits an overall upward trend, beginning at $57.66 million in 2019 and projected to reach $135.07 million by 2024. The growth rate has been highly variable, with a peak of 54.99% in 2020, a decline to 4.15% in 2021, and a new high of 28.26% in 2022. The growth rate is expected to stabilize at around 7.20% in 2024.
The peak growth rates in 2020 and 2022 for the United States suggest periods of rapid expansion, likely due to increased adoption of PCM technology or favorable market conditions. The decrease in growth rate in 2021 and the anticipated stabilization in 2024 may indicate market maturation or the influence of external factors such as economic conditions or regulatory changes. Overall, the market is expected to continue growing, albeit at a more moderate pace in the coming years.
Figure United States Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage Revenue (M USD) and Growth (2019-2024)
5.2 Canada Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage Market Revenue and Growth Analysis (2019-2024)
From 2019 to 2024, the revenue and growth rate of pharmaceutical continuous manufacturing (PCM) equipment for solid dosage in Canada have experienced unusual fluctuations. Revenue drastically dropped to $0 in 2020, then rebounded to $8.55 million in 2021, only to plummet back to $0 in 2022. There was a significant increase in 2023, reaching $8.49 million, with an expected substantial growth in 2024, projected to be $17.07 million. The growth rate mirrors these fluctuations, with a -100% decrease in 2020 and 2022, peaking at 0% in 2021, and an extraordinary surge to 101.12% in 2024. This data suggests a highly volatile market in Canada, with periods of no revenue followed by periods of growth, indicating that the market may be unstable or subject to one-off events affecting the industry.
Figure Canada Pharmaceutical Continuous Manufacturing (PCM) Equipment for Solid Dosage Revenue (M USD) and Growth (2019-2024)
